Meanwhile, GLP-1 receptor antagonists such as liraglutide, semaglutide, ALT-801, and dulaglutide promote pancreatic insulin production and inhibit glucagon secretion in protecting against NAFLD development. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.